Agilent Technologies Inc. has agreed to acquire Seahorse Bioscience, a provider of instruments and assay kits for measuring cell metabolism and bioenergetics, for $235 million.

Seahorse Bioscience technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics for cellular bioenergetics data. Seahorse Bioscience is privately held Seahorse and is headquartered in Billerica, Massachusetts, with manufacturing operations in Chicopee, Massachusetts. Regional offices are in Copenhagen, Denmark, and Shanghai, China. Seahorse Bioscience employs just under 200 people, most of whom are expected to join Agilent.

The acquisition is expected to be completed by November 1, 2015, subject to local laws and regulations and customary closing conditions.

Source: Agilent Technologies